Shares in drug reference content software vendor Epocrates Inc. rose more than 20 percent soon after trading started for its initial public offering of stock on Feb. 2.
The San Mateo, Calif.-based company raised its price before trading started from $13-15 to $16 per share. That raised the potential value of the IPO to $98.6 million. Epocrates' technology enables clinicians to access drug information via mobile computing devices at the point of care.
More information is available at epocrates.com.
Register or login for access to this item and much more
All Health Data Management content is archived after seven days.
Community members receive:
- All recent and archived articles
- Conference offers and updates
- A full menu of enewsletter options
- Web seminars, white papers, ebooks
Already have an account? Log In
Don't have an account? Register for Free Unlimited Access